DexCom, Inc. DXCM NDXSPX
Healthcare · Medical Devices · United States
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
READ MORE ›$73.74
-14.06% 1Y
Market & Price
Market Cap
$28.45B
Current Price
$73.74
High / Low (52W)
$89.53 / $54.84
Beta
1.40
Valuation
Stock P/E
31.65
Industry PE
23.65
Forward P/E
24.04
PEG Ratio
1.37
Book Value
$7.66
Price to Book
9.62
P/S
5.91
EV/EBITDA
21.22
Dividend Yield
-
Profitability & Returns
ROCE
26.37%
ROE
35.62%
ROA
9.65%
Profit Margin
19.31%
Op Margin
21.42%
EPS (Latest Qtr)
$0.51
EPS (TTM)
$2.33
Balance Sheet & Liquidity
Debt/Equity
0.47
Quick Ratio
1.58
Current Ratio
1.95
Debt
$1.38B
Total Assets
$6.34B
Current Assets
$4.03B
Working Capital
$1.89B
Ownership
Promoter Holding
0.27%
Chg in Prom Hold
-
FII / Inst Holding
102.65%
Chg in FII Hold
0.09%
Financial Snapshot
Enterprise Value
$27.42B
Total Revenue (TTM)
$4.82B
EBITDA
$1.29B
Free Cash Flow
$1.06B
Operating Cash Flow
$1.78B
Shares Outstanding
385.87M
Gross Margin
61.50%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
17.01%
Profit 5Y
34.83%
Revenue (YoY)
15.00%
Earnings (YoY)
92.20%
PROS
- Strong return on equity of 35.6%.
- Healthy ROCE of 26.4%.
- Compounding revenue at 17.0% over 5 years.
- Profit CAGR of 34.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DXCM DexCom, Inc. NDXSPX | 73.74 | 31.65 | $28.45B | - | 26.37% | 35.62% | 17.01% | 34.83% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 142.30M | 170.60M | 184.60M | 221.00M | 184.40M | 242.50M | 266.70M | 338.00M | 280.50M | 336.40M | 396.30M | 462.80M | 405.10M | 451.80M | 500.90M | 505.00M | 595.10M | 650.20M | 628.80M | 696.20M | 769.60M | 741.50M | 871.30M | 975.00M | 921.00M | 1.00B | 994.20M | 1.04B | 1.16B | 1.21B | 1.26B | 1.19B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 447.00M | 468.30M | 477.90M | 466.90M | 441.60M |
| Gross Profit | 46.50M | 66.00M | 74.70M | 91.20M | 75.10M | 85.50M | 101.10M | 116.70M | 94.10M | 117.50M | 127.00M | 153.50M | 118.90M | 153.60M | 168.60M | 222.80M | 168.80M | 206.50M | 246.90M | 309.30M | 256.50M | 284.10M | 340.40M | 343.90M | 417.10M | 446.90M | 398.10M | 449.50M | 494.20M | 462.60M | 546.40M | 623.30M | 561.90M | 626.70M | 593.80M | 589.00M | 688.80M | 731.40M | 792.70M | 750.30M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 455.30M | 476.20M | 488.90M | 469.70M | 495.00M |
| Operating Income | -12.70M | -3.60M | -42.40M | - | -19.20M | -20.10M | -18.50M | - | -40.40M | -13.60M | -500.00K | - | -30.70M | -4.90M | 13.90M | - | -14.40M | -800.00K | 56.00M | - | 33.60M | 67.80M | 94.10M | 45.90M | 101.00M | 118.30M | 41.30M | 77.00M | 147.50M | 47.20M | 128.10M | 205.50M | 101.10M | 158.00M | 152.00M | 133.70M | 212.60M | 242.50M | 323.00M | 255.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 219.00M | 308.80M | 420.60M | 410.10M | 339.70M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.70M | 4.70M | 4.70M | 4.20M | 3.10M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.30M | 241.10M | 352.30M | 340.70M | 269.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.90M | 61.30M | 68.50M | 73.40M | 70.00M |
| Net Income | -12.90M | -3.70M | -42.50M | 1.50M | -19.20M | -20.20M | -18.80M | -7.40M | -41.70M | 2.90M | -2.00M | -9.40M | -24.20M | 30.20M | 46.60M | -179.70M | -26.90M | -10.50M | 45.80M | 92.70M | 19.90M | 46.30M | 72.20M | 56.50M | 78.40M | 87.30M | 97.30M | 50.90M | 101.20M | 48.60M | 115.90M | 120.70M | 146.40M | 143.50M | 134.60M | 105.40M | 179.80M | 283.80M | 267.30M | 199.50M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.49 | 0.03 | -0.02 | -0.11 | -0.28 | 0.34 | 0.52 | -2.03 | -0.30 | -0.12 | 0.50 | 1.00 | 0.21 | 0.48 | 0.73 | 0.56 | 0.19 | 0.21 | 0.23 | 0.12 | 0.24 | 0.12 | 0.28 | 0.29 | 0.36 | 0.35 | 0.34 | 0.27 | 0.45 | 0.70 | 0.68 | 0.51 |
| R&D Expense | 19.80M | 24.40M | 64.80M | - | 32.20M | 36.30M | 43.90M | - | 48.10M | 45.30M | 43.30M | - | 44.80M | 47.20M | 50.10M | - | 59.00M | 69.00M | 66.70M | - | 73.10M | 79.90M | 87.70M | 109.40M | 129.10M | 128.80M | 135.90M | 121.70M | 110.30M | 119.00M | 119.30M | 131.40M | 141.50M | 136.00M | 135.40M | 145.20M | 148.20M | 157.50M | - | 145.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 573.30M | 718.50M | 1.03B | 1.48B | 1.93B | - | 2.91B | 3.62B | 4.03B | 4.66B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03B | 1.33B | 1.59B | 1.86B |
| Gross Profit | 3.66M | 18.40M | 35.90M | 46.60M | 100.10M | 176.30M | 278.40M | 378.40M | 492.10M | 663.90M | 931.50M | 1.28B | - | 1.88B | 2.29B | 2.44B | 2.80B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.49B | 1.69B | 1.84B | 1.89B |
| Operating Income | -45.83M | -45.30M | -44.80M | -55.70M | -28.90M | -21.50M | -57.10M | -63.90M | -42.50M | -186.30M | 142.30M | 299.50M | - | 391.20M | 597.70M | 600.00M | 911.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 565.30M | 916.70M | 945.70M | 1.36B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.60M | 20.30M | 19.00M | 18.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 390.80M | 710.40M | 709.00M | 1.09B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.60M | 168.90M | 132.80M | 252.10M |
| Net Income | -53.52M | -55.20M | -44.70M | -54.50M | -29.80M | -22.40M | -57.60M | -65.60M | -50.20M | -127.10M | 101.10M | 549.70M | - | 341.20M | 541.50M | 576.20M | 836.30M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.58 | -1.44 | 1.10 | 1.33 | - | 0.82 | 1.30 | 1.42 | 2.09 |
| R&D Expense | 14.29M | 23.20M | 29.60M | 38.30M | 44.80M | 69.40M | 137.50M | 156.10M | 185.40M | 199.70M | 273.50M | 359.90M | 517.10M | 484.20M | 505.80M | 552.40M | 599.10M |
Compounded Sales Growth
| 5 Years: | 17.01% |
| 1 Year: | 15.00% |
Compounded Profit Growth
| 5 Years: | 34.83% |
| 1 Year: | 92.20% |
Stock Price Performance
| 1 Year: | -14.06% |
| 6 Months: | +19.53% |
| 3 Months: | +0.42% |
| 1 Month: | +28.11% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 77.16M | 120.50M | 106.00M | 122.50M | 184.60M | 292.00M | 402.80M | 904.10M | 1.92B | 2.40B | 4.29B | - | 5.39B | 6.26B | 6.48B | 6.34B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.67B | 4.43B | 4.30B | 4.03B |
| Cash & Equivalents | 12.70M | 3.60M | 4.90M | 2.60M | 8.10M | 43.20M | 71.80M | 86.10M | 94.50M | 441.50M | 1.14B | 446.20M | 817.60M | - | 642.30M | 566.30M | 606.10M | 917.70M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 306.70M | 559.60M | 542.60M | 629.10M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 713.30M | 973.90M | 1.01B | 1.22B |
| Total Liabilities | - | - | 16.17M | 16.00M | 29.00M | 38.40M | 44.40M | 70.80M | 119.00M | 484.70M | 1.25B | 1.51B | 2.46B | - | 3.26B | 4.20B | 4.38B | 3.59B |
| Current Liabilities | - | - | 15.13M | 14.70M | 19.50M | 32.10M | 40.60M | 66.90M | 102.40M | 138.90M | 222.40M | 360.20M | 614.10M | - | 1.84B | 1.56B | 2.93B | 2.14B |
| Long Term Debt | - | - | - | - | 7.00M | 6.80M | 4.60M | - | - | - | - | - | - | - | 1.20B | 2.43B | 1.24B | 1.24B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.15B | 2.59B | 2.59B | 1.39B |
| Total Equity | - | - | - | - | - | - | - | - | - | - | 663.30M | 882.60M | 1.55B | - | 2.13B | 2.07B | 2.10B | 2.75B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 393.20M | 407.20M | 408.90M | 410.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -39.39M | -42.70M | -30.10M | -33.10M | 2.40M | 23.60M | 49.00M | 56.20M | 92.00M | 123.20M | 314.50M | 475.60M | - | 669.50M | 748.50M | 989.50M | 1.44B |
| Investing Cash Flow | -14.10M | -25.60M | -46.40M | 28.40M | 20.90M | -16.80M | -51.50M | -55.90M | -144.40M | -139.80M | -1.02B | -1.02B | - | -521.50M | -507.20M | -207.50M | 536.00M |
| Financing Cash Flow | 44.38M | 69.60M | 74.20M | 10.20M | 11.80M | 21.80M | 16.80M | 8.10M | 399.10M | 710.40M | 10.70M | 912.10M | - | -552.50M | -318.60M | -734.80M | -1.69B |
| Capital Expenditure | -2.99M | -6.90M | -8.00M | -9.50M | -7.90M | -16.20M | -33.30M | -55.70M | -66.00M | -67.10M | -180.00M | -199.00M | - | -364.80M | -236.60M | -358.80M | -363.50M |
| Free Cash Flow | -42.38M | -49.60M | -38.10M | -42.60M | -5.50M | 7.40M | 15.70M | 500.00K | 26.00M | 56.10M | 134.50M | 276.60M | - | 304.70M | 511.90M | 630.70M | 1.08B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -404.50M | -77.30M | 47.20M | 290.30M |
| Share Buybacks | - | - | - | - | - | - | - | 0 | 0 | 100.00M | 0 | 0 | 0 | 557.70M | 688.70M | 750.00M | 500.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 66.0% | 68.5% | 64.4% | 63.1% | 66.4% | - | 64.7% | 63.2% | 60.5% | 60.1% |
| Operating Margin % | - | - | - | - | - | - | - | -11.1% | -5.9% | -18.1% | 9.6% | 15.5% | - | 13.4% | 16.5% | 14.9% | 19.6% |
| Net Margin % | - | - | - | - | - | - | - | -11.4% | -7.0% | -12.3% | 6.8% | 28.5% | - | 11.7% | 14.9% | 14.3% | 17.9% |
| ROE % | - | - | - | - | - | - | - | - | - | -19.2% | 11.5% | 35.4% | - | 16.0% | 26.2% | 27.4% | 30.5% |
| ROCE % | - | -73.0% | -42.3% | -64.4% | -32.0% | -14.9% | -25.4% | -21.3% | -5.6% | -11.0% | 7.0% | 8.1% | - | 11.0% | 12.7% | 16.9% | 21.7% |
Shareholding Pattern
Insiders
0.27%
Institutions
102.65%
Public Float
102.93%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.10% | 38.96M | $2.87B |
| 2 | Vanguard Capital Management LLC | 6.48% | 25.02M | $1.85B |
| 3 | Vanguard Portfolio Management LLC | 4.98% | 19.22M | $1.42B |
| 4 | State Street Corporation | 4.65% | 17.93M | $1.32B |
| 5 | BAILLIE GIFFORD & CO | 4.04% | 15.60M | $1.15B |
| 6 | Alliancebernstein L.P. | 3.35% | 12.92M | $952.99M |
| 7 | Geode Capital Management, LLC | 3.20% | 12.35M | $910.44M |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.53% | 9.75M | $718.68M |
| 9 | Wellington Management Group, LLP | 2.42% | 9.33M | $687.72M |
| 10 | Amundi | 1.64% | 6.33M | $466.96M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DXCM
No recent headlines available.